Myriad RBM and Bio-Rad Laboratories said this week that they are partnering to develop and distribute immunoassay kits.

The deal gives Bio-Rad exclusive distribution rights, for research purposes, to Myriad RBM's catalog of quantitative multiplexed immunoassays to run on Bio-Rad's Bio-Plex 200, Bio-Plex 3D, and Bio-Plex MagPix instruments.

According to Sam LaBrie, vice president of corporate development at Myriad RBM, the agreement provides Myriad RBM with access to Bio-Rad's customer base – much of which Myriad RBM has not traditionally targeted.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.